



PRESS RELEASE

PsychoGenics and Roche Expand Their Drug Discovery Partnership

TARRYTOWN, N.Y., April 22, 2014 – PGI Drug Discovery LLC (PsychoGenics) announced that it has expanded its CNS drug discovery partnership with Roche and extended the agreement for another five years.

In April 2008, PsychoGenics and Roche entered into a drug discovery and development agreement to combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. The teams utilize the phenotypic approach in a high throughput manner with SmartCube[®] to drive chemistry optimization efforts.

“We are delighted to expand our shared-risk partnership with Roche. We have enjoyed an excellent working relationship with the talented Roche discovery team and look forward to advancing this promising discovery program” remarked Emer Leahy, Ph.D., PsychoGenics’ President & Chief Executive Officer.

PsychoGenics’ technologies, which include its SmartCube[®] system, combine broad *in vivo* behavioral expertise with developments in robotics, computer vision, and bioinformatics to phenotypically evaluate drug candidates with potential utility across the spectrum of CNS disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds; as well as, early stage compounds with novel mechanisms of action.

About PsychoGenics

PsychoGenics is a leader in *in vivo* phenotypic drug discovery. The Company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for neuropsychiatric disorders. PsychoGenics’ capabilities also include standard behavioral testing, electrophysiology, molecular biology, and state-of-the-art microdialysis. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington’s disease, autism spectrum disorders, psychosis/schizophrenia, Alzheimer’s disease, Parkinson’s disease, Spinal Muscular Atrophy, muscular dystrophy and other muscle disorders.

For more information contact:

Dr. Emer Leahy
President & CEO
Ph: (914) 406-8000
Email: info@psychogenics.com
www.psychogenics.com